We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VWR's New Kitting Center in Czech Republic to Boost EMEA Arm
Read MoreHide Full Article
VWR Corporation announced opening of a new kitting center in Skalice, Czech Republic on the eve of the company to be taken over by Avantor. Per VWR, this new 35,000 square foot facility is strategically located and will be helpful for the company’s business in the high-prospect EMEA (Europe, the Middle East and Africa) region.
Notably, this new center will particularly help expand Therapak’s (acquired by VWR in 2016) existing footprint in Europe with advanced facility and comprehensive kitting services for regional as well as global customers.
Location wise, this new center will assist the company’s VWRCATALYST offering to grow. This apart, proximity of this site to major industrial freight carrier hubs will enhance service levels compared with VWR’s current model. The facility will be fully operational on Oct 2, 2017.
Notably, VWRCATALYST Clinical and Biorepository Services lend a complete solution to its global regulated research and product development clients in the pharma, biopharma, manufacturing and clinical trial industries. Earlier in 2017, VWRCATALYST acquired laboratory and medical equipment, plus the ancillary supplier MESM and an international biorepository services organization, EPL Archives.
In this regard we note that over the last couple of years, VWR’s EMEA-APAC (Asia Pacific) segment has been experiencing an increase in comparable net sales, backed by several strategic initiatives implemented in recent times. This includes a series of plans to significantly upgrade its information technology infrastructure, optimize distribution network and modify marketing schemes.
In the recently-reported second quarter, on an organic basis, net sales in EMEA-APAC improved 2.7%. Going forward, management expects the EMEA-APAC segment to continue its run of strong historical progress.
However, the presence of a large number of players has made the medical devices market intensely competitive. In general, VWR competes with players like Thermo Fisher Scientific (TMO - Free Report) , Agilent Technologies, Inc. (A - Free Report) and PerkinElmer, Inc. .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
VWR's New Kitting Center in Czech Republic to Boost EMEA Arm
VWR Corporation announced opening of a new kitting center in Skalice, Czech Republic on the eve of the company to be taken over by Avantor. Per VWR, this new 35,000 square foot facility is strategically located and will be helpful for the company’s business in the high-prospect EMEA (Europe, the Middle East and Africa) region.
Notably, this new center will particularly help expand Therapak’s (acquired by VWR in 2016) existing footprint in Europe with advanced facility and comprehensive kitting services for regional as well as global customers.
Location wise, this new center will assist the company’s VWRCATALYST offering to grow. This apart, proximity of this site to major industrial freight carrier hubs will enhance service levels compared with VWR’s current model. The facility will be fully operational on Oct 2, 2017.
Notably, VWRCATALYST Clinical and Biorepository Services lend a complete solution to its global regulated research and product development clients in the pharma, biopharma, manufacturing and clinical trial industries. Earlier in 2017, VWRCATALYST acquired laboratory and medical equipment, plus the ancillary supplier MESM and an international biorepository services organization, EPL Archives.
In this regard we note that over the last couple of years, VWR’s EMEA-APAC (Asia Pacific) segment has been experiencing an increase in comparable net sales, backed by several strategic initiatives implemented in recent times. This includes a series of plans to significantly upgrade its information technology infrastructure, optimize distribution network and modify marketing schemes.
In the recently-reported second quarter, on an organic basis, net sales in EMEA-APAC improved 2.7%. Going forward, management expects the EMEA-APAC segment to continue its run of strong historical progress.
However, the presence of a large number of players has made the medical devices market intensely competitive. In general, VWR competes with players like Thermo Fisher Scientific (TMO - Free Report) , Agilent Technologies, Inc. (A - Free Report) and PerkinElmer, Inc. .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>